Magnesium therapy, fibrinolytic parameters and von Willebrand factor in acute myocardial infarction.
Sixty-one patients with non-thrombolytic treated acute myocardial infarction were randomised to open magnesium infusion or control. tPA activity, tPA mass, PAI-1 mass and von Willebrand factor (vWF) were measured in blood samples drawn at entrance and after on average 10 h and 18 h following inclusion in the trial. No differences for the hemostatic variables assay type were detected between the two groups. Fluctuations in the fibrinolytic parameters were maintained in the magnesium group, but blunted in the control group regarding PAI-mass and tPA-activity. This study gives no evidence that magnesium infusion in acute myocardial infarction influences fibrinolytic parameters or vWF.
Thögersen
A M
AM
Department of Internal Medicine, University Hospital, Umeå, Sweden.
Jansson
J H
JH
Wester
P O
PO
D000368:Aged; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005342:Fibrinolysis / Q000502:physiology*; D006801:Humans; D007262:Infusions, Intravenous; D008278:Magnesium Sulfate / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D010974:Platelet Aggregation / Q000187:drug effects; D012189:Retrospective Studies; D010959:Tissue Plasminogen Activator / Q000097:blood; D014672:Vectorcardiography; D014841:von Willebrand Factor / Q000187:drug effects / Q000378:metabolism*
D017395:Plasminogen Activator Inhibitor 1; D014841:von Willebrand Factor; D008278:Magnesium Sulfate; D010959:Tissue Plasminogen Activator